Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb Study Evaluating a Long-Acting Intramuscular Regimen of GSK1265744 Plus TMC278 For The Maintenance of Virologic Suppression Following an Induction of Virologic Suppression on an Oral Regimen of GSK1265744 Plus Abacavir/Lamivudine in HIV-1 Infected, Antiretroviral Therapy-Naive Adult Subjects

NCT02120352 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.

NCT NCT02120352
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02120352 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb Study Evaluating a Long-Acting Intramuscular Regimen of GSK1265744 Plus TMC278 For The Maintenance of Virologic Suppression Following an Induction of Virologic Suppression on an Oral Regimen of GSK1265744 Plus Abacavir/Lamivudine in HIV-1 Infected, Antiretroviral Therapy-Naive Adult Subjects
Lead sponsor
ViiV Healthcare
Phase
Phase 2
Overall status
Completed
Start date
April 28, 2014
Completion date
April 20, 2023
Enrollment
309 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections, infection, human immunodeficiency virus